Compare Chevron Corp (CVX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Recursion Pharmaceuticals Inc — how do they compare? Chevron Corp trades at $194.8 (market cap $382.34B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.78B). The key difference: Chevron Corp is far larger — about 214.8× Recursion Pharmaceuticals Inc's market cap, and Chevron Corp pays a 3.65% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CVX | RXRX | |
|---|---|---|
Market Cap | $382.34B | $1.78B |
Volume | 9,807,834 | — |
Sector | Energy | Health |
52-Week High | $211.14 | $6.79 |
52-Week Low | $146.72 | $2.84 |
Enterprise Value | $410.88B | $1.30B |
Dividend Yield | 3.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chevron (CVX) trades at $196.66, up 5.41% today, reflecting strong momentum amid high oil prices. The stock shows bullish technical signals, with recent earnings beats and a consensus analyst price target of $214.25. Revenue declined to $184.43B in 2025, but net income margin held at 9.87%, with robust cash flow from operations of $33.94B. Recent news highlights strategic investments in Argentina and Greece, leveraging geopolitical tensions to boost production prospects.
Outlook is positive with oil price tailwinds and operational efficiency, but risks include volatile energy markets and debt increases. The stock offers a solid dividend yield and growth potential, supported by analyst bullishness, though investors should monitor execution on new projects and macroeconomic shifts affecting energy demand.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
